Last reviewed · How we verify
ARGX-213
Monoclonal antibody targeting CD20
Monoclonal antibody targeting CD20 Used for Chronic inflammatory demyelinating polyneuropathy (CIDP).
At a glance
| Generic name | ARGX-213 |
|---|---|
| Sponsor | argenx |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
ARGX-213 is a monoclonal antibody that targets CD20, a protein expressed on the surface of B cells. By binding to CD20, ARGX-213 induces B cell depletion, which can be beneficial in the treatment of certain autoimmune diseases.
Approved indications
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
Common side effects
- Infusion-related reaction
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARGX-213 CI brief — competitive landscape report
- ARGX-213 updates RSS · CI watch RSS
- argenx portfolio CI